All In Biotech

Drug Trial Radar · NCT01371825

Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency

An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 (Sebelipase Alfa) in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency

Last checked: Nov 20, 2026Latest source record: Jan 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

9

Actual

Start

May 4, 2011

Primary completion

Jan 3, 2018

Study completion Jan 3, 2018

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Jun 13, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, up to 24 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was an open-label, repeat-dose, intra-participant dose-escalation study of SBC-102 (sebelipase alfa) in children with growth failure due to lysosomal acid lipase (LAL) Deficiency. Eligible participants received once-weekly (qw) infusions of sebelipase alfa for up to 5 years.

Conditions

  • Lysosomal Acid Lipase Deficiency
  • Wolman Disease

Interventions

  • Sebelipase alfa (SBC-102)Drug

    Sebelipase alfa is a recombinant human lysosomal acid lipase enzyme. The investigational medicinal product is an enzyme replacement therapy intended for treatment of participants with LAL Deficiency. Dosing occurred qw for up to 5 years.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Of Participants In The Primary Efficacy Analysis Set (PES) Surviving To 12 Months Of AgeTime frame: Month 12

Locations

7 sites in 5 countries. Site status is shown where the registry gives one.

  • Site not named

    Irvine, California

  • Site not named

    Cairo, Egypt

  • Site not named

    Grenoble, France

  • Site not named

    Paris, France

  • Site not named

    Dublin, Ireland

  • Site not named

    London, United Kingdom

  • Site not named

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.